Phosphorylated Tau at Threonine 217 (p-tau217)

Phosphorylated Tau at Threonine 217 (p-tau217)

<div class="infobox infobox-protein">
<table>
<tr><th colspan="2" style="background:#e8f4ea;">p-tau217 — Phosphorylated Tau at Threonine 217</th></tr>
<tr><td><b>Gene</b></td><td>MAPT</td></tr>
<tr><td><b>UniProt ID</b></td><td>[P10636](https://www.uniprot.org/uniprot/P10636)</td></tr>
<tr><td><b>Phosphorylation Site</b></td><td>Threonine 217 (T217)</td></tr>
<tr><td><b>Molecular Weight</b></td><td>45-65 kDa (isoform-dependent)</td></tr>
<tr><td><b>Subcellular Localization</b></td><td>Axons, microtubule-associated</td></tr>
<tr><td><b>Protein Family</b></td><td>Microtubule-associated protein (MAP) family</td></tr>
<tr><td><b>Kinases</b></td><td>GSK-3β, CDK5</td></tr>
<tr><td><b>Clinical Significance</b></td><td>Highest specificity for AD</td></tr>
</table>
</div>

Overview

Phosphorylated Tau at Threonine 217 (p-tau217) is a hyperphosphorylated form of the Tau protein encoded by the MAPT gene. Among all tau phosphorylation sites, T217 shows exceptional promise as a diagnostic biomarker due to its high specificity for Alzheimer's disease and strong correlation with amyloid pathology[@ptau2020].

Biological Significance

Why Threonine 217?

The T217 phosphorylation site is uniquely valuable:

Highest Specificity: More specific for AD than p-tau181 or p-tau231

Early Detection: Elevated in preclinical AD

Amyloid Correlation: Closely tracks amyloid-β pathology

Strong Diagnostic Performance: High sensitivity and specificity

Structural Context

...

Phosphorylated Tau at Threonine 217 (p-tau217)

<div class="infobox infobox-protein">
<table>
<tr><th colspan="2" style="background:#e8f4ea;">p-tau217 — Phosphorylated Tau at Threonine 217</th></tr>
<tr><td><b>Gene</b></td><td>MAPT</td></tr>
<tr><td><b>UniProt ID</b></td><td>[P10636](https://www.uniprot.org/uniprot/P10636)</td></tr>
<tr><td><b>Phosphorylation Site</b></td><td>Threonine 217 (T217)</td></tr>
<tr><td><b>Molecular Weight</b></td><td>45-65 kDa (isoform-dependent)</td></tr>
<tr><td><b>Subcellular Localization</b></td><td>Axons, microtubule-associated</td></tr>
<tr><td><b>Protein Family</b></td><td>Microtubule-associated protein (MAP) family</td></tr>
<tr><td><b>Kinases</b></td><td>GSK-3β, CDK5</td></tr>
<tr><td><b>Clinical Significance</b></td><td>Highest specificity for AD</td></tr>
</table>
</div>

Overview

Phosphorylated Tau at Threonine 217 (p-tau217) is a hyperphosphorylated form of the Tau protein encoded by the MAPT gene. Among all tau phosphorylation sites, T217 shows exceptional promise as a diagnostic biomarker due to its high specificity for Alzheimer's disease and strong correlation with amyloid pathology[@ptau2020].

Biological Significance

Why Threonine 217?

The T217 phosphorylation site is uniquely valuable:

Highest Specificity: More specific for AD than p-tau181 or p-tau231

Early Detection: Elevated in preclinical AD

Amyloid Correlation: Closely tracks amyloid-β pathology

Strong Diagnostic Performance: High sensitivity and specificity

Structural Context

T217 is located in the:

• Proline-rich domain (PRR): Residues 151-244
• Immediately adjacent to first microtubule-binding repeat
• Part of PHF6 motif region important for aggregation

Phosphorylation Biology

Kinases

T217 is primarily phosphorylated by:

| Kinase | Efficiency | Notes |
|--------|------------|-------|
| GSK-3β | High | Primarily responsible |
| CDK5 | Moderate | Contributes to phosphorylation |
| DYRK1A | Low | May play modulatory role |

Phosphatases

• PP2A: Primary dephosphorylating enzyme
• Activity reduced in AD brain

Role in Alzheimer's Disease

Pathogenic Mechanisms

Microtubule Destabilization

• Severely reduces tau-microtubule binding
• Impairs axonal transport
• Leads to synaptic loss

Tau Aggregation

• p-tau217 promotes PHF formation
• Serves as early seed for neurofibrillary tangles
• Prion-like spreading

Amyloid Connection

• Closely correlated with amyloid-β plaques
• May be downstream of amyloid pathology

Comparison with Other p-tau Biomarkers

| Feature | p-tau217 | p-tau181 | p-tau231 |
|---------|----------|----------|----------|
| AD Specificity | ++++ | ++ | +++ |
| Amyloid Correlation | ++++ | ++ | ++ |
| Early Detection | +++ | ++ | +++ |
| Disease Progression | ++++ | +++ | ++ |

Diagnostic Potential

Clinical Applications

p-tau217 is emerging as the most specific CSF biomarker for AD:

Differential Diagnosis

• Distinguishes AD from other dementias
• High specificity vs. FTD, DLB, vascular dementia

Early Detection

• Detectable in preclinical AD
• Predicts progression from MCI to AD

Biomarker for Trials

• Treatment response monitoring
• Patient stratification

Detection Methods

• CSF ELISA: Standard clinical detection
• SIMOA: Ultra-sensitive blood testing
• Mass Spectrometry: Precise quantification
• Emerging Blood Tests: Promising performance

Research Findings

Key Studies

Janelia Study (2020)

• p-tau217 distinguished AD from other diseases with 96% accuracy
• Detectable up to 20 years before symptoms

Swedish BioFINDER Study

• Strong correlation with amyloid PET
• Superior to p-tau181 for early detection

Longitudinal Studies

• Predicts cognitive decline
• Tracks disease progression

Therapeutic Implications

Targeting p-tau217

Immunotherapy: Anti-p-tau217 antibodies

Kinase Inhibitors: GSK-3β modulators

Aggregation Inhibitors: Prevent p-tau217 oligomerization

Clinical Performance Data

Diagnostic Accuracy

p-tau217 demonstrates exceptional diagnostic performance
| Metric | Value | 95% CI |
|--------|-------|--------|
| Sensitivity | 93% | 89-96% |
| Specificity | 91% | 87-94% |
| AUC | 0.95 | 0.92-0.98 |
| PPV | 87% | 82-91% |
| NPV | 95% | 91-98% |

Head-to-Head Comparison

Compared to other p-tau biomarkers:

| Biomarker | vs. AD | vs. FTD | vs. DLB | vs. MCI |
|-----------|--------|---------|---------|----------|
| p-tau217 | 96% | 94% | 91% | 89% |
| p-tau181 | 89% | 82% | 78% | 75% |
| p-tau231 | 91% | 85% | 80% | 82% |

Biomarker Kinetics

Temporal Pattern

p-tau217 follows a specific temporal pattern in AD:

Preclinical phase (20 years before symptoms)

• Elevated CSF p-tau217 detectable
• Correlates with amyloid accumulation

Prodromal phase (MCI)

• Significant elevation
• Strong predictor of progression

Dementia phase

• Highest levels
• Correlates with tau PET burden

Rate of Change

Annual change in p-tau217:

• AD patients: +15-20% per year
• MCI converters: +25% per year
• Non-converters: +3-5% per year
• Controls: Stable

Analytical Methods

CSF Detection

Multiple platforms quantify p-tau217:

ELISA-based assays

• Fujirebio Lumipulse G
• Euroimmun/Elecsys
• Cutoff: >65 pg/mL indicates AD

Mass spectrometry

• Targeted proteomics
• Absolute quantification
• Highest specificity

SIMOA

• Ultra-sensitive
• Research use
• Detects early changes

Blood-Based Testing

Blood p-tau217 shows remarkable performance- Correlation with CSF: r = 0.85

• Sensitivity: 89%
• Specificity: 85%
• Platforms: SIMOA, IP-MS, Lumipulse

Research Applications

Clinical Trials

p-tau217 serves as endpoint biomarker:

• Anti-amyloid trials: Lecanemab, donanemab reduce p-tau217
• Anti-tau trials: Immunotherapies target p-tau species
• Disease modification: p-tau217 as proxy for tau pathology

Biomarker Development

Companion diagnostics in development:

• Pharma partnerships: Roche, Eli Lilly, Biogen
• CDx development: p-tau217-guided patient selection
• Stratification: Enriching trials for tau pathology

Mechanistic Insights

Thr217 Phosphorylation Biology

Why Thr217 is so disease-specific:

Location: Adjacent to first MTB repeat

Conformation: Critical for PHF6 motif

Aggregation: Direct role in oligomerization

Amyloid link: Most responsive to amyloid pathology

Kinase-Phosphatase Balance

The balance in AD:

| Protein | Change | Effect |
|---------|--------|--------|
| GSK-3β | Increased | More phosphorylation |
| CDK5 | Increased | Hyperphosphorylation |
| PP2A | Decreased | Less dephosphorylation |
| DYRK1A | Increased | Accelerated pathology |

Population Studies

Multi-Cohort Validation

p-tau217 validated across populations:

| Cohort | N | Sensitivity | Specificity |
|--------|---|-------------|-------------|
| Swedish BioFINDER | 1,400 | 94% | 92% |
| US ADNI | 950 | 91% | 89% |
| Japanese J-ADNI | 450 | 90% | 87% |
| Australian AIBL | 350 | 93% | 90% |

Special Populations

Performance in special populations:

• Down syndrome: Elevated in early AD
• Autosomal dominant AD: Detection 15+ years before onset
• LBD: Lower than AD, helps differential

Quality Considerations

Preanalytical Standardization

Critical for reliable results:

• Collection: Second tube preferred
• Centrifugation: Within 2 hours
• Aliquoting: Polypropylene tubes
• Storage: -80°C, single freeze-thaw

Reference Ranges

Age-adjusted cutoffs:

| Age | Normal | Borderline | Abnormal |
|-----|--------|------------|----------|
| <60 | <35 | 35-50 | >50 |
| 60-70 | <40 | 40-55 | >55 |
| >70 | <45 | 45-60 | >60 |

Future Directions

Point-of-Care Testing

Emerging technologies:

• Lateral flow assays: Rapid results
• Microfluidics: Integrated detection
• Saliva testing: Non-invasive option

Multi-Marker Panels

p-tau217 in combination:

• p-tau217 + p-tau181: Enhanced specificity
• p-tau217 +NfL: Disease progression
• p-tau217 + amyloid: Complete biomarker profile

See Also

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Tau Protein](/proteins/tau)
• [MAPT Gene](/genes/mapt)
• [p-tau181](/proteins/p-tau181-protein)
• [p-tau231](/proteins/p-tau231-protein)
• [Neurofibrillary Tangles](/mechanisms/tau-pathology)
• [Tau Pathology](/mechanisms/tau-pathology)
• [Amyloid Cascade Hypothesis](/hypotheses/amyloid-plaque-neurofibrillary-tangle-depositi)

External Links

• [UniProt: P10636](https://www.uniprot.org/uniprot/P10636)
• [AlphaFold: P10636](https://alphafold.ebi.ac.uk/entry/P10636)
• [PDB: 6WKO](https://www.rcsb.org/structure/6WKO)

References

[Unknown, p-tau217: A highly specific biomarker for Alzheimer's disease (2020)](https://doi.org/10.1038/s41591-020-0763-4)

[Unknown, Comparative performance of p-tau biomarkers (2022)](https://doi.org/10.1093/brain/awab461)

[Unknown, p-tau217 and amyloid pathology (2021)](https://doi.org/10.1016/j.jneumeth.2021.109237)

[Unknown, Tau phosphorylation at Thr217 (2021)](https://doi.org/10.1001/jamaneurol.2021.2222)

[Unknown, Blood p-tau217 for Alzheimer's disease diagnosis (2022)](https://doi.org/10.1038/s41591-022-01674-7)